Valuation: Delcath Systems, Inc.

Market Cap 487M 436M 401M 364M 680M 46.26B 692M 4.79B 1.92B 24.33B 1.83B 1.79B 76.74B P/E 2026 *
-93.6x
P/E 2027 * -176x
Enterprise Value 487M 436M 401M 364M 680M 46.26B 692M 4.79B 1.92B 24.33B 1.83B 1.79B 76.74B EV / Sales 2026 *
4.59x
EV / Sales 2027 * 3.69x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
1 day-4.10%
1 week-2.64%
1 month-12.09%
3 months+14.89%
6 months+35.26%
Current year+39.01%
1 week 13.91
Extreme 13.91
15.24
1 month 13.91
Extreme 13.91
15.97
Current year 8.48
Extreme 8.485
17.42
1 year 8.12
Extreme 8.12
17.42
3 years 2.25
Extreme 2.25
18.23
5 years 2.25
Extreme 2.25
18.23
10 years 2.25
Extreme 2.25
398,780,487.8
Manager TitleAgeSince
Chief Executive Officer 62 01/10/2020
Director of Finance/CFO 47 01/05/2023
Chief Operating Officer 55 18/03/2024
Director TitleAgeSince
Chairman 62 16/02/2023
Director/Board Member 70 14/02/2020
Director/Board Member 60 06/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
13/10/26
Rosalind Advisors, Inc.
ConversionCompany -36 0.3911%
13/10/26
Rosalind Advisors, Inc.
ConversionCompany 31,129 0.0897%
13/05/26 Free

Director

22,500 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
-4.10%-2.64%+42.83%+345.71% 487M
+1.56%+2.41%-14.09%+12.32% 184B
-0.59%+1.18%+6.44%+36.82% 118B
-6.38%-4.98%-18.07%+8.01% 111B
+3.42%+1.71%-41.92%+8.01% 94.58B
+0.09%-0.05%-2.06%+78.69% 63.13B
-0.46%+0.42%+4.48%+82.84% 55.66B
-0.23%-0.52%+10.73%-21.72% 53.9B
-4.30%-1.64%-12.44%+37.99% 43.42B
+0.58%+2.00%-1.17%-8.82% 34.68B
Average -1.04%-0.21%-2.53%+57.98% 75.89B
Weighted average by Cap. -0.49%+0.24%-10.10%+23.96%

Financials

2026 *2027 *
Net sales 106M 95.12M 87.5M 79.28M 148M 10.08B 151M 1.04B 419M 5.3B 399M 390M 16.73B 132M 118M 109M 98.52M 184M 12.53B 188M 1.3B 520M 6.59B 495M 485M 20.79B
Net income -5.72M -5.12M -4.71M -4.27M -7.98M -543M -8.13M -56.21M -22.56M -286M -21.47M -21.01M -901M -3.39M -3.03M -2.79M -2.53M -4.73M -322M -4.82M -33.28M -13.36M -169M -12.71M -12.44M -534M
Net Debt - -
Projected Income Statement - Annual - Delcath Systems, Inc.
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
156
Date Price Change Volume
30/10/26 $14.04 -4.10% 427,351
29/10/26 $14.64 -1.48% 239,253
28/10/26 $14.86 +0.75% 315,204
27/10/26 $14.75 +1.65% 245,071
26/10/26 $14.51 +0.62% 232,857
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Delcath Systems, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.04USD
Average target price
24.00USD
Spread / Average Target
+70.94%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Delcath Systems, Inc.
  1. Stock Market
  2. Stocks
  3. DCTH Stock